Results 231 to 240 of about 4,942 (259)

Hypercholesterolaemia treated with inclisiran

Ugeskrift for Læger
In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects.
Nerma Todorovac, Michael Skov Hansen, Frank Peter Elpert   +2 more
openaire   +1 more source

Real-World Efficacy and Safety of Inclisiran

Journal of the American College of Cardiology
CHOLINET is a single-country, multicenter, observational, prospective, phase 4 registry of Italian patients initiating inclisiran as part of clinical management. Reimbursement criteria (Italian Medicines Agency [AIFA], GU 231-03.10.2022) include patients at very high cardiovascular (CV) risk with LDL-C of ≥70 mg/dL on statin ± ezetimibe.
Paola Gargiulo, Federica Marzano, Mario Crisci, Rossella Marcucci, Dario Bruzzese, Alessandro Maloberti, Filippo Maria Sarullo, Gennaro Galasso, Ciro Indolfi, Giuseppe Musumeci, Antonella Corleto, Paolo Calabrò, Stefano Carugo, Gavino Casu, Amedeo Picciolo, Marco Matteo Ciccone, Claudio Bilato, Alberto Polimeni, Francesco Giallauria, Angelo Catalano, Leonardo De Luca, Giampaolo Niccoli, Elio Venturini, Marco Pepe, Roberta Montisci, Natale Daniele Brunetti, Giuseppe Patti, Italo Porto, Alberto Margonato, Marina Floresta, Saverio Muscoli, Matteo Cameli, Giuseppe Andò, Emilio Di Lorenzo, Martina Berteotti, Cristina Giannattasio, Silvia Sarullo, Ciro Formisano, Assunta Di Costanzo, Fabrizio Delnevo, Ferdinando Varbella, Arturo Cesaro, Monica Franzese, Costantino Mancusi, Sara Fontanarosa, Mariafrancesca Di Santo, Ciro Cotticelli, Fabrizio Perrone Filardi, Stefania Paolillo, Giovanni Esposito, Alberto Corsini, Pasquale Perrone Filardi   +51 more
openaire   +3 more sources

Inclisiran (Leqvio) monotherapy for LDL-cholesterol reduction.

The Medical letter on drugs and therapeutics
Inclisiran (Leqvio – Novartis), a subcutaneously injected small interfering RNA (siRNA) that decreases LDL-cholesterol (LDL-C) levels by reducing synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), has been approved by the FDA for use ...

semanticscholar   +1 more source

Inclisiran no tratamento da hipercolesterolemia

Revista Eletrônica Acervo Saúde
Objetivo: Analisar o mecanismo de ação, eficácia, segurança e principais estudos sobre o inclisiran no tratamento da hipercolesterolemia. Revisão bibliográfica: Hipercolesterolemia é um dos distúrbios metabólicos mais prevalentes no mundo. Embora as estatinas sejam os fármacos de escolha para o tratamento visando a redução do LDL Colesterol (LDL-C ...
José Marcos Girardi, Daniel Monteiro de Lauro Silva, Isadora Araújo Girardi, Camila Trindade de Abreu, Gabriela Campos de Paiva, Gustavo Coelho Tafuri Mota, Pedro Casali Groppo, Raquel Breder Moraes de Almeida, Flávia Araújo Girardi   +8 more
openaire   +1 more source

ARN de interferencia en terapias hipolipemiantes e Inclisirán en el Manejo de la Dislipidemia Aterosclerótica [RNA interference in lipid-lowering therapies: The emerging role of Inclisiran in atherosclerotic dyslipidemia management]

Sanitas. Revista arbitrada de ciencias de la salud
Objetivo: analizar el ARN de interferencia en terapias hipolipemiantes e Inclisirán en el manejo de la dislipidemia aterosclerótica desde la evidencia científica. Método.
María Gabriela Balarezo-García, Diego Armando Suárez-Páez, Christian Alexis Ávila-Díaz, Heydi Nicole Paguay-Pingos   +3 more
semanticscholar   +1 more source

EFFECTIVENESS OF INCLISIRAN IN COMBINATION WITH STATINS IN PATIENTS WITH CORONARY HEART DISEASE AND TYPE 2 DIABETES MELLITUS

Scientific and Innovative Therapy
Patients suffering from coronary heart disease and diabetes mellitus are classified as extremely high cardiovascular risk. Even with widespread use of statins, a significant portion of patients retain residual risk due to atherogenic dyslipidemia.
Анжела Муминова
semanticscholar   +1 more source

Abstract P2077: The Safety Profile of Inclisiran in Patients with Dyslipidemia : A Systematic Review and Meta-Analysis

Circulation
Introduction: Inclisiran is a novel drug that employs ribonucleic acid (RNA) interference to lower the levels of the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.
Maisha Maliha, Vikyath Satish, K. Chi, Sriram Sunil Kumar, Amrin Kharawala, Supreeti Behuria, Eleonora Gashi   +6 more
semanticscholar   +1 more source

UK deal over inclisiran

BMJ, 2020
Paula, Byrne, John, Cullinan, Barbara, Mintzes, Susan M, Smith   +3 more
openaire   +2 more sources

EFFICACY AND SAFETY OF INCLISIRAN IN OUTPATIENTS WITH RECENT ACUTE CORONARY SYNDROME

European Heart Journal, Supplement
Early and intensive low–density lipoprotein cholesterol (LDL–C) reduction after recent acute coronary syndrome (ACS) may reduce recurrent CV event risk.
G. Ratti, M. Grieco, F. Ratti, M. Cecere, T. Fedele, E. Russolillo, M. Mallardo, F. Scotto di Uccio   +7 more
semanticscholar   +1 more source

Efficacy, benefit and safety of inclisiran

Clínica e Investigación en Arteriosclerosis (English Edition)
Hypercholesterolemia is a causal factor of atherosclerotic cardiovascular disease (ASCVD), which is one of the main causes of morbidity and mortality in Spain. The reduction of LDL cholesterol (LDL-C) decreases the risk of ASCVD and adverse cardiovascular events.
openaire   +2 more sources